Patents by Inventor Erwin Schultz

Erwin Schultz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T-Cell Stimulatory Peptides From The Melanoma-Associated Chondroitin Sulfate Proteoglycan And Their Use
    Publication number: 20090169573
    Abstract: The present invention relates to melanoma-associated chondroitin sulfate proteoglycan (MCSP) epitopes recognized by T cells, especially by CD4+ T lymphocytes (short T-cells) and CD8+ T cells, on human melanoma cells.
    Type: Application
    Filed: October 20, 2005
    Publication date: July 2, 2009
    Inventors: Erwin Schultz, Gerold Schuler
  • Tumor antigens and CTL clones isolated by a novel procedure
    Patent number: 7351409
    Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.
    Type: Grant
    Filed: January 7, 2004
    Date of Patent: April 1, 2008
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
  • Isolated peptides which bind to HLA-B18 molecules and uses thereof
    Patent number: 7041502
    Abstract: A peptide, previously identified as a binding partner of HLA-B44, has now been found to bind to HLA-B18 forming a T cell epitope. The therapeutic and diagnostic ramifications of this are the subject of this invention, as are various products obtained in the course of the development of the invention.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: May 9, 2006
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Janine Bilsborough, Erwin Schultz, Christophe Panichelli, Thierry Boon, Pierre Van der Bruggen
  • Tumor antigens and CTL clones isolated by a novel procedure
    Publication number: 20040185033
    Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.
    Type: Application
    Filed: January 7, 2004
    Publication date: September 23, 2004
    Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
  • Mage-A3 peptides presented by HLA class molecules
    Patent number: 6716809
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.
    Type: Grant
    Filed: September 15, 1999
    Date of Patent: April 6, 2004
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Erwin Schultz, Pascal Chaux, Jacques van Snick, Bernard Lethe, Thierry Boon-Fallaur, Pierre van der Bruggan, Vincent Stroobant, Kris Thielemans, Jurgen Corthals, Carlo Heirman
  • Tumor antigens and CTL clones isolated by a novel procedure
    Patent number: 6710172
    Abstract: The present invention relates to nucleic acid molecules encoding antigenic peptides from MAGE molecules that bind to HLA. An example of the nucleic acid molecules of the present invention is a nucleic acid molecule coding for the peptide GVYDGREHTV (SEQ ID NO: 44), which peptide binds to HLA-A2. The nucleic acid molecules and the encoded antigenic peptides are useful for diagnosing and treating various pathological conditions.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: March 23, 2004
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catie Traversari, Vincent Stroobant, Guy R. Cornelis, Thierry Boon-Falleur, Pierre van der Bruggen, Erwin Schultz, Guy Warnier
  • Isolated peptides which bind to HLA-B18 molecules and uses thereof
    Publication number: 20030228325
    Abstract: A peptide, previously identified as a binding partner of HLA-B44, has now been found to bind to HLA-B18 forming a T cell epitope. The therapeutic and diagnostic ramifications of this are the subject of this invention, as are various products obtained in the course of the development of the invention.
    Type: Application
    Filed: June 5, 2002
    Publication date: December 11, 2003
    Inventors: Janine Bilsborough, Erwin Schultz, Christophe Panichelli, Thierry Boon-Falleur, Pierre Van der Bruggen
  • MAGE antigenic peptides which bind HLA-B35 and HLA-B44
    Publication number: 20020164654
    Abstract: The invention provides antigenic peptides derived from MAGE-A1 polypeptides and presented by HLA-B35 and HLA-B44 molecules. Antigenic peptides derived from MAGE-A3 polypeptides and presented by HLA-B35 molecules also are provided. Methods for diagnosis and treatment which involve the polypeptides also are provided.
    Type: Application
    Filed: January 19, 2001
    Publication date: November 7, 2002
    Inventors: Rosalie Luiten, Thierry Boon-Falleur, Pierre Van der Bruggen, Vincent Stroobant, Nathalie Demotte, Erwin Schultz